(NUWE) – Press Releases
-
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
-
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
-
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
-
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
-
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
-
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
-
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
-
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
-
Nuwellis Announces Board of Directors Transition
-
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
-
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
-
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
-
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
-
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
-
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
-
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results
-
Nuwellis Announces Plan for CFO Transition
-
Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
-
Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
-
Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
-
Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis, Inc. Announces First Quarter 2023 Financial Results
-
Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023
-
Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results
-
Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI)
-
Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
-
Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results
-
Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer
-
Nuwellis, Inc. Announces Passage of Warrant Proposal
-
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
-
Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements
-
Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex
-
Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
-
Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
-
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Nuwellis, Inc. Reports Third Quarter 2022 Financial Results
-
Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates
-
Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022
-
Nuwellis Announces Appointment of Chief Financial Officer
-
Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
-
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering
-
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
Back to NUWE Stock Lookup
